{"nctId":"NCT02300233","briefTitle":"The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia","startDateStruct":{"date":"2015-02-05","type":"ACTUAL"},"conditions":["Hypertriglyceridemia"],"count":114,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Volanesorsen 300 mg weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Volanesorsen"]},{"label":"Volanesorsen 300 mg biweekly, post Week 13","type":"EXPERIMENTAL","interventionNames":["Drug: Volanesorsen"]}],"interventions":[{"name":"Volanesorsen","otherNames":["ISIS 304801"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Body mass index (BMI) ≤ 45 kg/m2\n2. Fasting Triglycerides (TG) ≥ 500 mg/dL (≥ 5.7 mmol/L) at Screening.\n3. If on statin or fibrate, participants must be on stable, labeled dose for at least 3 months prior to screening. Participants not receiving these drugs within 4 weeks prior to screening are also eligible.\n\nExclusion Criteria:\n\n1. Type 1 diabetes mellitus\n2. Newly diagnosed type 2 diabetes mellitus (within 12 weeks of screening) or HbA1c ≥ 9.0% at Screening\n3. Acute pancreatitis within 3 months of screening\n4. Acute Coronary Syndrome within 6 months of screening\n5. Major surgery within 3 months of screening\n6. Prior exposure to ISIS 304801\n7. Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":null},{"groupId":"OG001","value":"-71.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Fasting TG From Baseline to Month 3","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"-869","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response Rate Defined as Participants With Fasting TG ≥ 40% Reduction From Baseline at Month 3","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-density Lipoprotein-cholesterol (HDL-C) From Baseline","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"61.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response Rate Defined as Participants With Fasting TG < 150 mg/dL Reduction From Baseline at Month 3","description":"mg/dL = milligrams per deciliter","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)","description":"HOMA-IR was calculated using the following formula: fasting insulin micro-international units per millimeter (μIU/mL) x fasting glucose mg/dL\\]/405. A negative change from baseline indicates improvement; a positive change from baseline indicates worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"3.12"},{"groupId":"OG001","value":"1.53","spread":"4.89"},{"groupId":"OG002","value":"-0.45","spread":"4.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"3.18"},{"groupId":"OG001","value":"1.54","spread":"7.69"},{"groupId":"OG002","value":"0.56","spread":"2.97"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycated Hemoglobin (HbA1c) in Type 2 Diabetes Mellitus (T2DM) Participants","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.5"},{"groupId":"OG001","value":"0.4","spread":"0.6"},{"groupId":"OG002","value":"0.1","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.6"},{"groupId":"OG001","value":"0.8","spread":"0.9"},{"groupId":"OG002","value":"0.3","spread":"0.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":38},"commonTop":["Injection site erythema","Injection site pain","Injection site swelling","Injection site pruritus","Injection site discolouration"]}}}